Media type: E-Article Title: mTORC 2:1 for Chemotherapy Sensitization in Glioblastoma Contributor: Wick, Wolfgang; Blaes, Jonas; Weiler, Markus imprint: American Association for Cancer Research (AACR), 2011 Published in: Cancer Discovery Language: English DOI: 10.1158/2159-8290.cd-11-0264 ISSN: 2159-8274; 2159-8290 Keywords: Oncology Origination: Footnote: Description: <jats:title>Abstract</jats:title> <jats:p>mTOR signaling is frequently deregulated in cancer, including brain tumors. Although the signaling of mTOR complex 1 (mTORC1) has been subject to intensive investigations and mTORC1 itself has been a well-established cancer drug target for years, the role of the second complex, mTORC2, remains elusive. Tanaka et al. reveal an EGFRvIII-mTORC2-NFκB signaling cascade and demonstrate that mTORC2 mediates cisplatin resistance through NF-κB in an Akt-independent manner in glioblastoma. Uncovering the role of mTORC2 in chemotherapy resistance in glioblastoma highlights the need for further investigations of mTORC2 inhibition. Cancer Discovery; 1(6); 475–76. ©2011 AACR.</jats:p> <jats:p>Commentary on Tanaka et al., p. 524.</jats:p> Access State: Open Access